Ensign Peak Advisors
BMY.RT

Ensign Peak Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Ensign Peak Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,986,676
Closed -$1.37M – 1936
2020
Q4 		$1.37M Buy
1,986,676
+1,295,999
+188% +$2.76M ﹤0.01% 1260
2020
Q3 		$1.55M Buy
690,677
+401,099
+139% +$1.15M ﹤0.01% 1105
2020
Q2 		$1.04M Buy
289,578
+26,590
+10% +$95.9K ﹤0.01% 1270
2020
Q1 		$1M Buy
262,988
+221,694
+537% +$730K ﹤0.01% 1169
2019
Q4 		$124K Buy
+41,294
New +$107K ﹤0.01% 1639

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Ensign Peak Advisors's BMY.RT Position: Q1 2021 in Review

Ensign Peak Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,986,676 shares — an estimated $1.37M sold.

Ensign Peak Advisors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.55M in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Ensign Peak Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Ensign Peak Advisors sold 1,986,676 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1.37M.
  • Ensign Peak Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Ensign Peak Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.55M in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Ensign Peak Advisors's 13F filing for Q1 2021, filed 12 May 2021.